PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808878
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1808878
Deep Brain Stimulation In Parkinson's Disease Market size was valued at US$ 910.28 Million in 2024, expanding at a CAGR of 10.30% from 2025 to 2032.
Deep Brain Stimulation (DBS) in Parkinson's Disease market refers to the global industry that focuses on devices, technologies, and services for treating Parkinson's disease with deep brain stimulation therapy. DBS is the surgical implantation of electrodes in specific areas of the brain to deliver controlled electrical impulses, which help manage motor symptoms such as tremors, stiffness, and bradykinesia that are not adequately controlled by medication. This market consists of implantable pulse generators (IPGs), electrodes, stimulation programming software, and post-implantation support services.
Deep Brain Stimulation In Parkinson's Disease Market- Market Dynamics
Rising prevalence of neurological disorders fuels market growth
The growing prevalence of neurological disorders is expected to drive the Deep Brain Stimulation In Parkinson's Disease Market in the coming years. Neurological disorders are a diverse group of diseases that affect the autonomic, peripheral, and central nervous systems. Deep brain stimulation systems are used in neurosurgical procedures to deliver electrical stimulation to the target area, with the goal of altering or modulating neural functioning and achieving a reversible, adjustable, and therapeutic effect. For instance, the Parkinson's Foundation, a US-based national organization, estimates that nearly 90,000 people were diagnosed with Parkinson's disease in the United States in March 2023, a 50% increase from the previously estimated rate of 60,000 diagnoses per year. As a result, the growing prevalence of neurological disorders is driving the growth of the Deep Brain Stimulation in Parkinson's Disease market.
Deep Brain Stimulation In Parkinson's Disease Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.30% over the forecast period (2025-2032)
Based on Product segmentation, Dual-channel is predicted to show maximum market share in the year 2025
Based on End-use segmentation, hospital is the leading End-use in 2025
On the basis of region, North America is the leading revenue generator in 2025
The Global Deep Brain Stimulation In Parkinson's Disease Market is segmented on the basis of Product, End-use, and Region.
The market is divided into two categories based on Product: Single-channel, and Dual-channel. The dual-channel segment will account for the largest share in 2025 due to its superior effectiveness in reducing patient tremors and improving overall quality of life. Dual-channel DBS devices provide greater control and precision in delivering electrical stimulation to specific brain regions, making them popular among neurosurgeons and patients alike. Dual-channel systems' robust performance and reliability have cemented their market leadership.
The market is divided into four categories based on End-use: Hospitals, Ambulatory Surgical Centers, Neurology Clinics, and Research Centers. The hospital segment will dominate the market in 2025. Hospitals are frequently equipped with advanced medical technology and specialized personnel, allowing them to provide comprehensive care to patients requiring DBS therapy. Many patients prefer hospitals because of the procedure's complexity and the need for continuous monitoring and support throughout the treatment process. Furthermore, hospitals typically provide a multidisciplinary approach that includes neurologists, neurosurgeons, and other healthcare professionals, improving patient outcomes through coordinated care. Because Parkinson's disease frequently presents with a variety of symptoms that necessitate ongoing management, hospitals are well-positioned to provide the comprehensive care required for effective treatment.
Deep Brain Stimulation In Parkinson's Disease Market- Geographical Insights
North America Deep Brain Stimulation will have the largest revenue share in the Parkinson's disease market in 2025. The region's dominance can be attributed to a variety of factors, including a high prevalence of Parkinson's disease, advanced healthcare infrastructure, and substantial government and private funding for research and development. Technological advancements, such as robot-assisted implantation and improved microelectrode designs, have boosted market growth in this region.
The Asia Pacific Deep Brain Stimulation In Parkinson's Disease Market is expected to grow the fastest over the forecast period. This rapid growth can be attributed to the rising prevalence of Parkinson's disease, rising healthcare costs, and increased awareness of DBS treatment. The region is also benefiting from technological advancements and the introduction of new DBS devices. Governments in the Asia Pacific region are actively encouraging the use of DBS therapy by providing favorable policies and funding for R&D.
Several major medical device companies drive innovation and market growth in the DBS market through research and development. Leading players improve their products and differentiate themselves with advanced technologies and patient-centric solutions. Several major players dominate the market, which is moderately consolidated. However, new companies and startups are increasing competition and technological advancements, improving DBS systems and patient outcomes. Medtronic, Boston Scientific, and Abbott are DBS market leaders with extensive neurostimulation device portfolios and global presence. One of the largest DBS manufacturers, Medtronic, offers systems with adaptive stimulation and MRI compatibility. Innovation and collaboration with research institutions have kept the company competitive. Boston Scientific, another major player, develops cutting-edge DBS therapy technologies to meet diverse patient needs.
In August 2024, Medtronic plc has received FDA approval for Asleep DBS surgery for Parkinson's and essential tremor patients. This novel approach allows patients to have DBS surgery while awake or asleep, increasing flexibility and comfort.